ReviewChildren (Basel, Switzerland)2021
Current Perspectives on Management of Type 2 Diabetes in Youth.
Review in Children (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled TrialsJournal of clinical research in pediatric endocrinology · 2024Pooled it
- A meta-analysis of the therapeutic effect of probiotic intervention in obese or overweight adolescents.Frontiers in endocrinology · 2024Pooled it
- The effects of probiotic administration on patients with prediabetes: a meta-analysis and systematic review.Journal of translational medicine · 2022Pooled it
- Chemical screening of Hibiscus rosa-sinensis for their phytochemicals and their in vitro/in silico evaluation as α-amylase inhibitors.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Planetary health diet, other plant-based diets and risk of type 2 diabetes: a prospective study from the UK Biobank.Cardiovascular diabetology · 2025Article
- Less common forms of diabetes in young population.Pediatric endocrinology, diabetes, and metabolism · 2024Review
- Complications and Treatment of Early-Onset Type 2 Diabetes.International journal of endocrinology and metabolism · 2023Review
- Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.TouchREVIEWS in endocrinology · 2023Review
- Youth-Onset Type 2 Diabetes: Burden of Complications and Socioeconomic Cost.Current diabetes reports · 2023Review
- Contraception for Adolescents and Young Women with Type 2 Diabetes-Specific Considerations.Current diabetes reports · 2022Review
- Omics era in type 2 diabetes: From childhood to adulthood.World journal of diabetes · 2021Review
- Phytochemical Profiling in Conjunction withACS omega · 2021Article
- Bariatric Surgery in Adolescents: To Do or Not to Do?Children (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of type 2 diabetes mellitus (T2DM) in children and adolescents is on the rise, and the increase in prevalence of this disorder parallels the modern epidemic of childhood obesity worldwide. T2DM affects primarily post-pubertal adolescents from ethnic/racial minorities and those from socioeconomically disadvantaged backgrounds. Youth with T2DM often have additional cardiovascular risk factors at diagnosis. T2DM in youth is more progressive in comparison to adult onset T2DM and shows lower rates of response to pharmacotherapy and more rapid development of diabetes-related complications. Lifestyle modifications and metformin are recommended as the first-line treatment for youth with T2DM in the absence of significant hyperglycemia. Assessment of pancreatic autoimmunity is recommended in all youth who appear to have T2DM. Pharmacotherapeutic options for youth with T2DM are limited at this time. Liraglutide, a GLP-1 agonist, was recently approved for T2DM in adolescents 10 years of age and older. Several clinical trials are currently underway with youth with T2DM with medications that are approved for T2DM in adults. Bariatric surgery is associated with excellent rates of remission of T2DM in adolescents with severe obesity and should be considered in selected adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.